

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of )  
 )  
**Miller** ) Atty. Dkt. **3024-114**  
 )  
Serial No. **National Stage of** )  
**PCT/EP2004/005213** ) Examiner: n/a  
 )  
Filed: herewith ) Group Art Unit: n/a

For: **One or several enzyme-containing compositions, dietetic food products and medicaments produced therefrom, and their use for medical purposes**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Under the provisions of 37 C.F.R. § 1.56, 1.97 and 1.98, Applicants submit on the attached form a listing of publications cited in the International Search Report for PCT/EP2004/005213, filed May 14, 2004, is attached. Copies of the documents should be part of the International Application File transmitted to the USPTO by the EPO (MPEP §1893.03(g)).

10/555244

JCO6 Rec'd PCT/PTO 31 OCT 2005

No fee is believed to be due. However, the Commisioner is authorized to charge deposit account no. 50-3135 as required for consideration of this submission.

Respectfully submitted,

By Joyce v. Natzmer  
Joyce von Natzmer  
Attorney for Applicants  
Registration No. 48,120  
4615 North Park Avenue, Suite 919  
(301) 657-1282

October 31, 2005

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number		Nat. Stage of PCT/EP2004/005213	
				Nat. Phase Filing Date		herewith	
				First Named Inventor		Miller	
				Group Art Unit		NA	
				Examiner Name		NA	
Sheet	2	of	2	Attorney Docket Number		3024-114	
<b>NON PATENT LITERATURE DOCUMENTS</b>							
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					T <sup>2</sup>
		Stauder et al., STRAHENTERAPUTISCHE NEBENWIRKUNGEN BEI ABDOMINALKREBSPATIENTEN UND DEREN REDUKTION DURCH HYDROLYTISCHE ENZYMPREPARATE („Radiation induced adverse reactions in abdominal cancr patients and theri reduction by hydrolytic enzymes“), Deutsche Zeitschrift für Onkologie, Heidelberg, DE, vol. 23, No. 1, pgs. 7-16 (1991).					
Examiner Signature						Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.